Rituximab for Pediatric Renal Transplant Rejection

Phase 2/3 Completed 20 enrolled Stanford University Genentech and Biogen IDEC · collab

RandomizedSingle-groupOpen-labelTreatment

Summary

Rituximab will be tested for its safety and potential efficacy in treating B cell dense renal allograft rejection episodes in children receiving renal transplants at Stanford University

Timeline

Start: 2005-06
Primary completion: —
Completion: 2007-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rituximab	Monoclonal antibody	375 mg/m2	Intravenous

Indications

No indication recorded.